To circumvent this methodological limitation and to rule out the possibility that upregulation of BCL2 is restricted to the pre-invasive stage of tumor development driven by CDH1 inactivation, we evaluated E-cadherin and BCL2 immunoreactivity in LCIS lesions. This evidence concerns the gene BCL2 and lobular breast carcinoma in situ.